Key facts
- This page summarizes Kirko Kirkov's Form 4 filing for ELITE PHARMACEUTICALS INC /NV/ (ELTP).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 25 Jul 2025, 18:05.
Kirko Kirkov - 10 Jul 2025 Form 4 Insider Report for ELITE PHARMACEUTICALS INC /NV/ (ELTP)
- Reporting relationship
- Chief Commercial Officer
- Issuer ticker
- ELTP
- Reported as of
- 10 Jul 2025
- Net transaction value
- +$9,640
- SEC form
- 4
- Accepted by SEC
- 25 Jul 2025, 18:05:07 UTC
- Prior SEC filing
- 14 Nov 2022
- Source filing
- View source filing
- Reporting owner signature
- Kirko Kirkov
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Filing notes and source
Key filing fact
Kirko Kirkov filed Form 4 for ELITE PHARMACEUTICALS INC /NV/ (ELTP) on 25 Jul 2025.
Change
- Previous filing in this sequence was filed on 14 Nov 2022.
- Current net transaction value: +$9,640.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001946043
Primary reporting owner
Kirkov Kirko
- Relationship
- Chief Commercial Officer
- Address
- 165 LUDLOW AVE, NORTHVALE
- Signature
- Kirko Kirkov
- Signature date
- 25 Jul 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ELTP
transaction
Common Stock
Purchase
- Transaction value
- $9,640
- Shares
- +16,366
- Change %
- Price
- $0.5890
- Shares after
- 16,366
- Date
- 10 Jul 2025
- Ownership
- Direct
* marks a reported price that did not pass the local price check.